THE IMPACT OF BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS ON THE COURSE OF RHEUMATOID ARTHRITIS-ASSOCIATED LUNG DISEASE

被引：0
|
作者：
Avsar, A. Koken [1 ]
Can, G. [1 ]
Birlik, M. [1 ]
Sari, I. [1 ]
Onen, F. [1 ]
机构：
[1] Dokuz Eylul Univ, Dept Rheumatol, Med Sch, Izmir, Turkey
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.3440
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0099
引用
收藏
页码：624 / 625
页数：2
相关论文
共 50 条
  • [1] EFFECT OF DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS ON LUNG MICROENVIRONMENT IN RHEUMATOID ARTHRITIS-ASSOCIATED LUNG DISEASE ANIMAL MODELS
    Chang, S. H.
    Lee, J. S.
    Chae, J. J.
    Choe, J. Y.
    Lee, E. Y.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 473 - 473
  • [2] RHEUMATOID-ARTHRITIS - DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    KIRWAN, JR
    CURREY, HLF
    [J]. CLINICS IN RHEUMATIC DISEASES, 1983, 9 (03): : 581 - 599
  • [3] Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis
    Kurata, Izumi
    Tsuboi, Hiroto
    Terasaki, Mayu
    Shimizu, Masaru
    Toko, Hirofumi
    Honda, Fumika
    Ohyama, Ayako
    Yagishita, Mizuki
    Osada, Atsumu
    Ebe, Hiroshi
    Kawaguchi, Hoshimi
    Takahashi, Hiroyuki
    Hagiwara, Shinya
    Asashima, Hiromitsu
    Kondo, Yuya
    Matsumoto, Isao
    Sumida, Takayuki
    [J]. INTERNAL MEDICINE, 2019, 58 (12) : 1703 - 1712
  • [4] Effects of disease-modifying anti-rheumatic drugs (DMARDs) on the activities of rheumatoid arthritis-associated cathepsins K and S
    Weidauer, Enrico
    Yasuda, Yoshiyuki
    Biswal, Bichitra K.
    Cherny, Maia
    James, Michael N. G.
    Bromme, Dieter
    [J]. BIOLOGICAL CHEMISTRY, 2007, 388 (03) : 331 - 336
  • [5] Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Monchablon, Clelia
    Gonde, Henri
    Pouplin, Sophie
    Varin, Remi
    Vittecoq, Olivier
    Lequerre, Thierry
    [J]. CLINICAL RHEUMATOLOGY, 2020, 39 (01) : 207 - 216
  • [6] Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Choy, Ernest
    Aletaha, Daniel
    Behrens, Frank
    Finckh, Axel
    Gomez-Reino, Juan
    Gottenberg, Jacques-Eric
    Schuch, Florian
    Rubbert-Roth, Andrea
    [J]. RHEUMATOLOGY, 2017, 56 (05) : 689 - 697
  • [7] Disease-modifying anti-rheumatic drugs in rheumatoid arthritis and ankylosing spondylitis
    Haibel, H.
    Specker, C.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2009, 27 (04) : S159 - S163
  • [8] Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Clélia Monchablon
    Henri Gondé
    Sophie Pouplin
    Rémi Varin
    Olivier Vittecoq
    Thierry Lequerré
    [J]. Clinical Rheumatology, 2020, 39 : 207 - 216
  • [9] ANA DEVELOPMENT IS ASSOCIATED WITH POOR RESPONSE TO BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Ishikawa, Y.
    Hashimoto, M.
    Ito, H.
    Tanaka, M.
    Yukawa, N.
    Fujii, T.
    Mimori, T.
    Terao, C.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 107 - 108
  • [10] Use of Disease-Modifying Anti-Rheumatic Drugs for Rheumatoid Arthritis in Quebec, Canada
    Roussy, Jean-Pascal
    Bessette, Louis
    Bernatsky, Sasha
    Rahme, Elham
    Legare, Jean
    Lachaine, Jean
    [J]. ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S855 - S855
12345